Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-08 04:10 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Director, Officer | OPT+S | $16.45 | 1,551 | $25,520 | 18,521 |
| 2025-05-08 04:09 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Officer | OPT+S | $16.45 | 1,691 | $27,824 | 20,355 |
| 2025-05-08 04:08 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Carruthers R Michael | Officer | OPT+S | $16.45 | 1,314 | $21,621 | 81,014 |
| 2025-05-08 04:09 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer | OPT+S | $16.45 | 5,187 | $85,348 | 21,588 |
| 2025-05-07 23:30 | 2025-05-05 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $7.30 | 820 | $5,986 | 345,659 |
| 2025-05-08 00:03 | 2025-05-06 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Director, Officer | SELL | $7.12 | 236 | $1,680 | 82,503 |
| 2025-05-07 18:48 | 2024-09-24 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% owner | BUY | $0.00 | 13,252,112 | $0 | 13,808,577 |
| 2025-05-08 04:10 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | Officer | OPT+S | $16.45 | 1,930 | $31,757 | 6,531 |
| 2025-05-08 04:10 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | KOCH KEVIN | Director, Officer | OPT+S | $16.45 | 4,276 | $70,358 | 20,619 |
| 2025-05-08 04:09 | 2025-05-05 | LFCR | LIFECORE BIOMEDICAL, INC. DE | English Aron R. | 10% owner | SELL | $7.05 | 41,091 | $289,868 | 1,714,070 |
| 2025-05-07 04:48 | 2025-05-02 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% owner | BUY | $4.50 | 45,000 | $202,302 | 4,247,670 |
| 2025-05-06 20:58 | 2025-05-05 | OGN | Organon & Co. | Ali Kevin | Director, Officer | BUY | $8.81 | 34,000 | $299,370 | 282,731 |
| 2025-05-07 03:53 | 2025-05-02 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $50.17 | 2,100 | $105,367 | 66,398 |
| 2025-05-06 23:05 | 2025-05-02 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Officer | OPT+S | $2.50 | 20,000 | $50,024 | 12,000 |
| 2025-05-07 04:47 | 2025-05-02 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% owner | BUY | $4.50 | 45,000 | $202,302 | 4,247,670 |
| 2025-05-06 23:45 | 2025-05-02 | BBIO | BridgeBio Pharma, Inc. | Apuli Maricel | Officer | SELL | $38.51 | 1,026 | $39,509 | 147,639 |
| 2025-05-06 23:29 | 2025-05-02 | AMRX | Amneal Pharmaceuticals Inc. | Patel Gautam | Director | SELL | $8.00 | 8,668 | $69,344 | 1,720,218 |
| 2025-05-06 23:42 | 2025-05-02 | BBIO | BridgeBio Pharma, Inc. | Lo Andrew | Director | SELL | $38.50 | 100,000 | $3,849,900 | 105,583 |
| 2025-05-07 04:48 | 2025-05-02 | ALMS | Alumis Inc. | Tananbaum James B. | Director, 10% owner | BUY | $4.50 | 45,000 | $202,302 | 4,247,670 |
| 2025-05-07 02:06 | 2025-05-02 | PRTA | PROTHENA CORP PUBLIC LTD CO | EcoR1 Capital, LLC | 10% owner | SELL | $8.10 | 6,279,684 | $50,839,694 | 5,304,596 |
| 2025-05-06 23:40 | 2025-05-02 | XNCR | Xencor Inc | Valente Nancy | Officer | SELL | $11.03 | 4,616 | $50,914 | 49,169 |
| 2025-05-06 20:59 | 2025-05-05 | OGN | Organon & Co. | WALSH MATTHEW M | Officer | BUY | $8.82 | 11,400 | $100,548 | 144,484 |
| 2025-05-07 01:52 | 2025-05-02 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $4.61 | 320,290 | $1,477,306 | 3,586,788 |
| 2025-05-06 23:37 | 2025-05-06 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $35.01 | 2,000 | $70,020 | 140,255 |
| 2025-05-07 00:07 | 2025-05-02 | BMRN | BIOMARIN PHARMACEUTICAL INC | Hubbard Cristin | Officer | SELL | $64.92 | 273 | $17,723 | 32,700 |
| 2025-05-06 00:34 | 2025-05-02 | DERM | Journey Medical Corp | Maraoui Claude | Director, Officer | SELL | $6.84 | 4,834 | $33,065 | 2,348,313 |
| 2025-05-06 00:34 | 2025-05-02 | DERM | Journey Medical Corp | Benesch Joseph | Officer | SELL | $6.84 | 2,409 | $16,478 | 203,557 |
| 2025-05-06 00:31 | 2025-05-02 | DERM | Journey Medical Corp | Alloush Ramsey | Officer | SELL | $6.84 | 2,857 | $19,542 | 504,817 |
| 2025-05-06 00:20 | 2025-05-02 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $15.20 | 5,030 | $76,453 | 204,399 |
| 2025-05-06 00:20 | 2025-05-02 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer | SELL | $15.19 | 11,448 | $173,917 | 913,795 |
| 2025-05-05 23:49 | 2025-05-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $14.64 | 10,000 | $146,357 | 111,944 |
| 2025-05-06 00:20 | 2025-05-02 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $15.19 | 2,597 | $39,442 | 119,339 |
| 2025-05-05 23:54 | 2025-05-02 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Officer | OPT+S | $28.00 | 10,122 | $283,416 | 9,415 |
| 2025-05-06 01:43 | 2025-05-01 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $20.05 | 7,500 | $150,391 | 990,188 |
| 2025-05-06 01:42 | 2025-05-01 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.06 | 7,500 | $150,416 | 977,892 |
| 2025-05-05 23:14 | 2025-05-02 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bhatia Sangeeta N. | Director | SELL | $505.86 | 400 | $202,344 | 4,831 |
| 2025-05-06 03:40 | 2024-06-06 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | Officer | BUY | $0.57 | 5,000 | $2,835 | 13,863 |
| 2025-05-06 03:35 | 2024-06-06 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Director, Officer | BUY | $0.57 | 5,000 | $2,835 | 38,772 |
| 2025-05-05 23:08 | 2025-05-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $10.02 | 26,631 | $266,952 | 33,998 |
| 2025-05-06 02:18 | 2025-04-21 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | Officer | SELL | $37.93 | 762 | $28,901 | 71,530 |
| 2025-05-06 04:54 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | OPT+S | $21.05 | 1,784 | $37,553 | 93,126 |
| 2025-05-06 04:53 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | OPT+S | $21.05 | 18,924 | $398,350 | 419,173 |
| 2025-05-06 04:53 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | OPT+S | $21.05 | 1,771 | $37,280 | 128,215 |
| 2025-05-06 04:52 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Officer | OPT+S | $21.05 | 3,198 | $67,318 | 100,241 |
| 2025-05-06 03:14 | 2025-05-02 | ARDX | Ardelyx Inc. | RAAB MICHAEL | Director, Officer | OPT+S | $4.25 | 41,666 | $177,168 | 1,594,754 |
| 2025-05-06 04:51 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $21.05 | 4,920 | $103,566 | 89,482 |
| 2025-05-06 03:22 | 2025-05-02 | ARDX | Ardelyx Inc. | MOTT DAVID M | Director | BUY | $4.22 | 381,377 | $1,610,936 | 2,396,871 |
| 2025-05-06 02:00 | 2025-05-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director, Officer | SELL | $117.57 | 1,500 | $176,350 | 438,807 |
| 2025-05-06 03:33 | 2025-05-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $72.13 | 39,410 | $2,842,769 | 85,622 |
| 2025-05-06 03:28 | 2025-05-02 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $72.90 | 40,000 | $2,915,920 | 2,941,985 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.